Brian J Werth1, William O Hahn2, Susan M Butler-Wu3, Robert M Rakita2. 1. 1 School of Pharmacy, University of Washington , Seattle, Washington. 2. 2 Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington. 3. 3 Department of Laboratory Medicine, University of Washington , Seattle, Washington.
Abstract
INTRODUCTION: We describe the clinical and microbiologic courses of two patients with ventricular assist device infections secondary to Corynebacterium striatum treated with daptomycin. In both cases, the pathogen was initially susceptible to daptomycin (minimum inhibitory concentration [MIC] <0.125 mg/L) but became resistant (MIC >256 mg/L) during therapy. METHODS: The clonal nature of the isolates was determined by pulse-field gel electrophoresis (PFGE). Daptomycin binding was assessed by fluorescence microscopy using daptomycin-boron-dipyrromethene (bodipy). Induction and stability of daptomycin resistance were assessed by culturing strains in the presence of low concentrations of daptomycin or passage of resistant strains on daptomycin-free medium and repeat MIC testing, respectively. RESULTS: PFGE revealed that resistant clinical isolates were genetically indistinguishable from their parent strains, but the two pairs were unrelated to each other. The resistant strains had 7.5-15 times lower binding of daptomycin-bodipy compared to the related susceptible strains (p ≤ 0.0002). High-level daptomycin resistance (MIC >256 mg/L) was generated in vitro for both susceptible parent strains after overnight culture in the presence of daptomycin. One of the resistant strains maintained a high-level resistance phenotype up to 5 days of passage on daptomycin-free medium, whereas the other strain reverted back to a susceptible phenotype (MIC = 0.38 mg/L) after one passage on daptomycin-free medium, with a concomitant increase in daptomycin binding. CONCLUSIONS: High-level daptomycin resistance in C. striatum was readily generated in vitro and during the course of therapy in these patients. This resistance appears to be mediated by reduced daptomycin binding. Providers should be cautious about using long-term daptomycin monotherapy for C. striatum infections.
INTRODUCTION: We describe the clinical and microbiologic courses of two patients with ventricular assist device infections secondary to Corynebacterium striatum treated with daptomycin. In both cases, the pathogen was initially susceptible to daptomycin (minimum inhibitory concentration [MIC] <0.125 mg/L) but became resistant (MIC >256 mg/L) during therapy. METHODS: The clonal nature of the isolates was determined by pulse-field gel electrophoresis (PFGE). Daptomycin binding was assessed by fluorescence microscopy using daptomycin-boron-dipyrromethene (bodipy). Induction and stability of daptomycin resistance were assessed by culturing strains in the presence of low concentrations of daptomycin or passage of resistant strains on daptomycin-free medium and repeat MIC testing, respectively. RESULTS: PFGE revealed that resistant clinical isolates were genetically indistinguishable from their parent strains, but the two pairs were unrelated to each other. The resistant strains had 7.5-15 times lower binding of daptomycin-bodipy compared to the related susceptible strains (p ≤ 0.0002). High-level daptomycin resistance (MIC >256 mg/L) was generated in vitro for both susceptible parent strains after overnight culture in the presence of daptomycin. One of the resistant strains maintained a high-level resistance phenotype up to 5 days of passage on daptomycin-free medium, whereas the other strain reverted back to a susceptible phenotype (MIC = 0.38 mg/L) after one passage on daptomycin-free medium, with a concomitant increase in daptomycin binding. CONCLUSIONS: High-level daptomycin resistance in C. striatum was readily generated in vitro and during the course of therapy in these patients. This resistance appears to be mediated by reduced daptomycin binding. Providers should be cautious about using long-term daptomycin monotherapy for C. striatum infections.
Authors: Truc T Tran; Siraya Jaijakul; Cole T Lewis; Lorena Diaz; Diana Panesso; Heidi B Kaplan; Barbara E Murray; Audrey Wanger; Cesar A Arias Journal: Antimicrob Agents Chemother Date: 2012-03-26 Impact factor: 5.191
Authors: Manuel L Fernández Guerrero; Antonio Molins; Manuel Rey; José Romero; Ignacio Gadea Journal: Int J Antimicrob Agents Date: 2012-07-18 Impact factor: 5.283
Authors: Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier Journal: N Engl J Med Date: 2009-11-17 Impact factor: 91.245
Authors: Allison R McMullen; Neil Anderson; Meghan A Wallace; Angela Shupe; C A Burnham Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: Edwin D Neas; Julie A Dunn; Evelyn Dimaano Silva; A Morgan Chambers; Gary J Luckasen; Adam Jaskowiak Journal: Adv Wound Care (New Rochelle) Date: 2016-10-01 Impact factor: 4.730
Authors: Kaitlin F Mitchell; Erin McElvania; Meghan A Wallace; Lauren E Droske; Amy E Robertson; Lars F Westblade; C A Burnham Journal: J Clin Microbiol Date: 2021-03-19 Impact factor: 5.948
Authors: Hussam Tabaja; Don Bambino Geno Tai; Elena Beam; Matthew P Abdel; Aaron J Tande Journal: Open Forum Infect Dis Date: 2022-04-14 Impact factor: 4.423